Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid? - Wikidata - awgldk - TriplyDB

Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?

Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?

http://www.wikidata.org/entity/Q35835005

about

Adult stem cells in neural repair: Current options, limitations and perspectives Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.Regulatory and clinical considerations for biosimilar oncology drugs Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers.Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control.

P2860

Q26824821-370F38EB-7921-4ADC-AA83-2D0E1CC567A4 Q35192785-844F12EB-AB79-4F44-8B8D-B8D3B505BAC5 Q35505833-8C7F7EC6-CBE7-4F10-B883-83AAD26A0E65 Q38628058-F882A220-CEB2-402C-A7EC-7EA9BD9945A9 Q38726241-E5C6BFAF-6E16-421B-8654-56B60CAD1C37 Q39385304-6C991673-C524-4A1B-A3F7-B15E72336ADD Q39504419-D2B1B7F9-1E15-4B18-9E24-BE2E8A21BF81 Q40141879-42D93B28-BE88-4ADA-B985-DCC38F72FA30 Q42181212-4F3D0D2B-DC6E-4FE4-9B22-0F7BDB92C531 Q53549083-30644564-08DB-4947-AF89-F990476075A7

P2860

Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?

http://www.wikidata.org/entity/Q35835005

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Biosimilar granulocyte-colony- ...... bilization: need we be afraid?

@ast

Biosimilar granulocyte-colony- ...... bilization: need we be afraid?

@en

type

label

Biosimilar granulocyte-colony- ...... bilization: need we be afraid?

@ast

Biosimilar granulocyte-colony- ...... bilization: need we be afraid?

@en

prefLabel

Biosimilar granulocyte-colony- ...... bilization: need we be afraid?

@ast

Biosimilar granulocyte-colony- ...... bilization: need we be afraid?

@en

P1433

Q35835005-5D2B1572-F1BD-4FB5-A273-B7CD08A2FDA2

P1476

Q35835005-960215EF-6172-4C10-AB87-B56AB18954A6

P2093

Q35835005-C8F28853-2205-4409-B671-552AAE20FEA5

Q35835005-DC0473B4-1CB2-4B4D-9758-406FF8CB2D0F

Q35835005-F48DE985-A980-45E4-B502-363156F8FFCA

P275

Q35835005-2441EE1A-7F72-43BA-A8C6-3D376D3B43EC

P2860

Q35835005-015F1FCC-913A-4D27-BBE8-B8033BEEB367

Q35835005-042CFD1B-8D4B-4E49-878E-551F99A3927B

Q35835005-08130841-7E64-4AF3-88C3-91CE2CE8E319

Q35835005-0E98407E-0DC1-40B6-9387-E2160995762C

Q35835005-0EA8275A-AB6D-4895-8017-42DC9619B253

Q35835005-14B7D7E0-01AA-4DB8-9FF0-C5C634DC21AA

Q35835005-1785DEBF-B4DF-4442-B3AB-4311C0283FF2

Q35835005-1AE005F3-A47C-4775-9FB0-5A36AD836081

Q35835005-1DB1029A-87A6-4EB5-A21B-70D3D9B89283

Q35835005-2071A1D2-0644-48E5-8419-DC5BB034E3F0

P304

Q35835005-C4F326FB-A28A-447D-AC22-5072E1B763D9

P31

Q35835005-3900E665-5740-4883-B34F-E694641F9475

P356

Q35835005-E6E526BC-B289-40FC-A2A7-FB313F26B81C

P433

Q35835005-F43E08E6-0DB2-4593-AEAE-3392A6AAA37E

P478

Q35835005-40EE48EA-A0BD-4705-966A-24CEED14CC14

P50

Q35835005-18EFE695-2CC0-4BA2-8E29-769D50615A2F

P577

Q35835005-76559C8A-2DAA-4D11-AB0D-4772DFEEB1A1

P5875

Q35835005-4E0E4F2A-A7FE-4739-BDDF-ACA3E6997348

P698

Q35835005-7530AB52-83A6-4E39-BFA1-E9271B6C326F

P921

Q35835005-49596448-12C0-4835-85E8-99ED0B66865D

Q35835005-8B5CF6FF-9967-4960-A5AF-6A6D0C59EDAA

Q35835005-9E243374-1647-4761-A704-4481325DB1C7

Q35835005-EB35C3F0-6E6D-45C6-B89B-B8500D88BBDF

P932

Q35835005-441201B6-EBE7-472F-966A-0DFB74249E4D

P356

P1433

P1476

Biosimilar granulocyte-colony- ...... bilization: need we be afraid?

@en

P2093

Arnd Schwebig

http://www.w3.org/2001/XMLSchema#string

Matthew Turner

http://www.w3.org/2001/XMLSchema#string

Petra S Becker

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary?

Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.

Effects and safety of granulocyte colony-stimulating factor in healthy volunteers

When biotech proteins go off-patent.

Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature.

Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.

B-lymphopoiesis is stopped by mobilizing doses of G-CSF and is rescued by overexpression of the anti-apoptotic protein Bcl2

P304

430-439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TRF.12770

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263510853

http://www.w3.org/2001/XMLSchema#string

P698

24965197

http://www.w3.org/2001/XMLSchema#string

P921

monoclonal antibody

P932

4497358

http://www.w3.org/2001/XMLSchema#string